CN111194222A - 与xCT抗体相关的组合物和方法 - Google Patents

与xCT抗体相关的组合物和方法 Download PDF

Info

Publication number
CN111194222A
CN111194222A CN201880028741.7A CN201880028741A CN111194222A CN 111194222 A CN111194222 A CN 111194222A CN 201880028741 A CN201880028741 A CN 201880028741A CN 111194222 A CN111194222 A CN 111194222A
Authority
CN
China
Prior art keywords
antibody
xct
seq
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880028741.7A
Other languages
English (en)
Chinese (zh)
Inventor
费德丽卡·佩里克莱
约翰·奥罗克
费德丽卡·卡瓦洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agilvax Inc
Original Assignee
Agilvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agilvax Inc filed Critical Agilvax Inc
Publication of CN111194222A publication Critical patent/CN111194222A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880028741.7A 2017-05-01 2018-04-30 与xCT抗体相关的组合物和方法 Pending CN111194222A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492912P 2017-05-01 2017-05-01
US62/492,912 2017-05-01
PCT/US2018/030276 WO2018204278A1 (en) 2017-05-01 2018-04-30 COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES

Publications (1)

Publication Number Publication Date
CN111194222A true CN111194222A (zh) 2020-05-22

Family

ID=64016266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028741.7A Pending CN111194222A (zh) 2017-05-01 2018-04-30 与xCT抗体相关的组合物和方法

Country Status (7)

Country Link
US (1) US11059901B2 (enExample)
EP (1) EP3618869A4 (enExample)
JP (1) JP2020518668A (enExample)
CN (1) CN111194222A (enExample)
AU (1) AU2018261720A1 (enExample)
CA (1) CA3060590A1 (enExample)
WO (1) WO2018204278A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
JP2024542030A (ja) 2021-10-29 2024-11-13 ブイアイビー ブイゼットダブリュ 慢性創傷治癒のための手段および方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719521A (zh) * 2011-03-31 2012-10-10 上海市肿瘤研究所 胱氨酸/谷氨酸反向转体xCT抑制剂在肝癌治疗中的应用
CN102803967A (zh) * 2009-04-07 2012-11-28 基督教高等教育科学研究及病人护理协会 用于结直肠腺癌的诊断的基于蛋白质的方法和组合物
CN105837686A (zh) * 2016-05-27 2016-08-10 洛阳普莱柯万泰生物技术有限公司 一种单克隆抗体及其应用
WO2017052679A1 (en) * 2015-09-21 2017-03-30 The United States Of America, As Represented By The Secretary, Departmnet Of Health & Human Service Monoclonal antibodies specific for heartland virus and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
CA2481507A1 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003232453A1 (en) * 2002-05-30 2003-12-19 David K. Bol Human solute carrier family 7 member 11 (hslc7a11)
CN109152811A (zh) * 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803967A (zh) * 2009-04-07 2012-11-28 基督教高等教育科学研究及病人护理协会 用于结直肠腺癌的诊断的基于蛋白质的方法和组合物
CN102719521A (zh) * 2011-03-31 2012-10-10 上海市肿瘤研究所 胱氨酸/谷氨酸反向转体xCT抑制剂在肝癌治疗中的应用
WO2017052679A1 (en) * 2015-09-21 2017-03-30 The United States Of America, As Represented By The Secretary, Departmnet Of Health & Human Service Monoclonal antibodies specific for heartland virus and methods of their use
CN105837686A (zh) * 2016-05-27 2016-08-10 洛阳普莱柯万泰生物技术有限公司 一种单克隆抗体及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANN MASSIE等: "Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats" *
JOERI VAN LIEFFERINGE等: "Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed" *
JOHNAN A. R. KALEEBA等: "Kaposi\'s Sarcoma-Associated Herpesvirus Fusion-Entry Receptor: Cystine Transporter xCT" *
TAKATSUGU ISHIMOTO等: "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth" *

Also Published As

Publication number Publication date
JP2020518668A (ja) 2020-06-25
CA3060590A1 (en) 2018-11-08
US20200148784A1 (en) 2020-05-14
WO2018204278A1 (en) 2018-11-08
EP3618869A4 (en) 2021-01-20
EP3618869A1 (en) 2020-03-11
US11059901B2 (en) 2021-07-13
AU2018261720A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US20250333533A1 (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
ES2927090T3 (es) Anticuerpo anti-TROP-2 humano que muestra actividad antitumoral in vivo
RU2673724C2 (ru) Белки специфического связывания и их применения
US9790274B2 (en) Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
KR20200016899A (ko) 활성화가능 항-pdl1 항체, 및 이의 이용 방법
JP2022528061A (ja) 抗クローディン１８．２抗体及びその用途
ES2753419T3 (es) Inhibidores del factor H del complemento
JP2015501639A (ja) 抗ｃｄ９８抗体およびその使用方法
BR112012029281B1 (pt) anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
JP2023089245A (ja) Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
JP2017505107A (ja) Ｃｃｒ９に対する抗体およびその用途
CN117343187A (zh) 对muc18特异性的抗体
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
CN111194222A (zh) 与xCT抗体相关的组合物和方法
CN114641307A (zh) 抗cd19抗体及其用途
US10030072B2 (en) Method of generating antibodies
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
HK40069328A (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
HK40060753A (en) Antibodies specific to muc18
BR112021006431A2 (pt) anticorpos direcionados a epn1
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof
BR112017005002B1 (pt) Anticorpo humano isolado que se liga especificamente a cd46, imunoconjugado, formulação farmacêutica, uso de um anticorpo, ácido nucleico e vetor de expressão
BR112014020816B1 (pt) Anticorpos monoclonais anti-sez6, conjugado anticorpo-fármaco e composições farmacêuticas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200522